{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:10:30Z","timestamp":1792440630730,"version":"4.5.0"},"reference-count":59,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This study aimed to perform a systematic review and meta-analysis to evaluate motor function and safety outcomes in Chinese patients with spinal muscular atrophy (SMA) treated with nusinersen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched across multiple databases, including PubMed, Cochrane, Embase, Web of Science, CNKI, CBM, Wanfang, and VIP, for real-world studies (RWS) published before 15 February 2026. Data extraction is performed based on predefined study selection and eligibility criteria, while excluding studies involving non-Chinese populations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>24 RWS were included in this analysis, comprising 1,273 Chinese patients with SMA Types 1\u20134 treated with nusinersen. Statistically significant improvements were found in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) [Mean Difference (MD)\u2009=\u20096.57 (95% CI: 4.35\u20138.80)], Hammersmith Infant Neurological Examination Section 2 (HINE-2) [MD\u2009=\u20092.05 (95% CI: 0.94\u20133.16)], Hammersmith Functional Motor Scale Expanded (HFMSE) [MD\u2009=\u20094.71 (95% CI: 3.10\u20136.32)], Revised Upper Limb Module (RULM) [MD\u2009=\u20093.70 (95% CI: 2.47\u20134.93)], and the 6-minute walk test (6MWT) [MD\u2009=\u200924.96\u2005m (95% CI: 16.20\u201333.72)] at the end of the follow-up period. In terms of clinical response rate, CHOP-INTEND (\u22654 points) was 71.80% (95%CI: 56.14%\u201385.65%), HFMSE (\u22653 points) was 59.71%(95%CI: 43.79%\u201374.74%), RULM(\u22652 points) was 60.35% (95%CI:48.67%\u201371.51%), respectively. As treatment duration increased, motor function scores and clinical response rates either improved or stabilized. When the treatment duration reached \u226514 months, the pooled mean change from baseline was as follows: CHOP-INTEND [MD\u2009=\u20099.45 (95% CI: 5.03\u201313.87)], HFMSE [MD\u2009=\u20094.37 (95% CI: 3.34\u20135.40)]], and RULM [MD\u2009=\u20092.83 (95% CI: 1.97\u20133.68)]. Clinical response rates were: 76.41% (95% CI: 52.89%\u201394.57%) for CHOP-INTEND, 69.83% (95% CI: 48.60%\u201387.61%) for HFMSE, and 63.23% (95% CI: 45.86%\u201379.13%) for RULM. The overall adverse event (AE) rate was 41.27% (95% CI: 29.65%\u201353.38%), with serious AEs occurring in 1.26% (95% CI: 0%\u20135.85%) of Chinese patients. The most common AEs were headache, back pain, and post-lumbar puncture syndrome, associated with the lumbar puncture administration method.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our meta-analysis indicates that nusinersen is associated with a statistically significant and clinically meaningful improvement in motor function among Chinese patients with types 1\u20134 SMA in real-world studies. The reported adverse events align with the expected safety profile of nusinersen. However, the majority of studies included in this review had a follow-up period of less than 24 months. Therefore, further long-term follow-up is necessary to assess the sustained therapeutic effects of nusinersen in Chinese patients with SMA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD42023403580<\/jats:ext-link>\n                      , PROSPERO CRD42023403580.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fped.2026.1767428","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T06:47:19Z","timestamp":1773384439000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Motor function and safety of nusinersen for spinal muscular atrophy: a systematic review and meta-analysis among Chinese patients"],"prefix":"10.3389","volume":"14","author":[{"given":"Guanlan","family":"He","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, Maternal and Child Health Hospital of Guangxi Zhuang Autonomous Region","place":["Nanning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zilu","family":"Feng","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Guangxi Medical University","place":["Nanning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Maternal and Child Health Hospital of Guangxi Zhuang Autonomous Region","place":["Nanning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shasha","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Maternal and Child Health Hospital of Guangxi Zhuang Autonomous Region","place":["Nanning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunyuan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Maternal and Child Health Hospital of Guangxi Zhuang Autonomous Region","place":["Nanning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuneng","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Maternal and Child Health Hospital of Guangxi Zhuang Autonomous Region","place":["Nanning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1016\/S0140-6736(08)60921-6","article-title":"Spinal muscular atrophy","volume":"371","author":"Lunn","year":"2008","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"278","DOI":"10.13748\/j.cnki.issn1007-7693.20232544","article-title":"Meta-analysis of nusinersen in improving respiratory and nutritional support and safety in children with spinal muscular atrophy","volume":"42","author":"He","year":"2025","journal-title":"Chin J Mod Appl Pharm"},{"key":"B3","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s13023-017-0671-8","article-title":"Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review","volume":"12","author":"Verhaart","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"B4","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41434-024-00503-8","article-title":"Gene-based therapy for the treatment of spinal muscular atrophy types 1 and 2: a systematic review and meta-analysis","volume":"32","author":"Chongmelaxme","year":"2025","journal-title":"Gene Ther"},{"key":"B5","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.brainres.2012.01.044","article-title":"Spinal muscular atrophy: the role of SMN in axonal mRNA regulation","volume":"1462","author":"Fallini","year":"2012","journal-title":"Brain Res"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1007\/s12325-024-03101-7","article-title":"Motor function and safety of nusinersen and risdiplam in Asian patients with types 2-4 spinal muscular atrophy (SMA): a systematic review and meta-analysis","volume":"42","author":"Zhao","year":"2025","journal-title":"Adv Ther"},{"key":"B7","doi-asserted-by":"publisher","first-page":"11939","DOI":"10.3390\/ijms241511939","article-title":"Spinal muscular atrophy: the past, present, and future of diagnosis and treatment","volume":"24","author":"Nishio","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1007\/s40263-021-00878-x","article-title":"Nusinersen: a review in 5q spinal muscular atrophy","volume":"35","author":"Hoy","year":"2021","journal-title":"CNS Drugs"},{"key":"B9","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ (Clinical Researched)"},{"key":"B10","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1002\/mus.25430","article-title":"Revised upper limb module for spinal muscular atrophy: development of a new module","volume":"55","author":"Mazzone","year":"2017","journal-title":"Muscle Nerve"},{"key":"B11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3969\/j.issn.1673-5501","article-title":"Practice guidelines for spinal muscular atrophy","volume":"18","year":"2023","journal-title":"Chin J Evid-Based Pediatr"},{"key":"B12","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1002\/mus.26419","article-title":"Revised upper limb module for spinal muscular atrophy: 12 month changes","volume":"59","author":"Pera","year":"2019","journal-title":"Muscle Nerve"},{"key":"B13","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1002\/mus.25120","article-title":"Six-minute walk test is reliable and valid in spinal muscular atrophy","volume":"54","author":"Dunaway Young","year":"2016","journal-title":"Muscle Nerve"},{"key":"B14","author":"Wells","year":""},{"key":"B15","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1186\/s12885-021-08154-3","article-title":"Efficacy and safety of apatinib in the treatment of osteosarcoma: a single-arm meta-analysis among Chinese patients","volume":"21","author":"Yao","year":"2021","journal-title":"BMC Cancer"},{"key":"B16","doi-asserted-by":"publisher","first-page":"316","DOI":"10.3969\/j.issn.1002-3674","article-title":"Meta-analysis and software implementation with an individual occurrence rate of 0 or 1","volume":"39","author":"Yue","year":"2022","journal-title":"Chin J Health Stat"},{"key":"B17","doi-asserted-by":"publisher","first-page":"Ed000142","DOI":"10.1002\/14651858.ED000142","article-title":"Updated guidance for trusted systematic reviews: a new edition of the cochrane handbook for systematic reviews of interventions","volume":"10","author":"Cumpston","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"B18","doi-asserted-by":"publisher","first-page":"688","DOI":"10.3760\/cma.j.cn112140-20211223-01075","article-title":"Clinical follow-up analysis of nusinersen in the disease-modifying treatment of pediatricspinal muscular atrophy","volume":"60","author":"Mao","year":"2022","journal-title":"Chin J Pediatr"},{"key":"B19","doi-asserted-by":"publisher","first-page":"743","DOI":"10.7499\/j.issn.1008-8830.2401082","article-title":"Clinical efficacy of nusinersen sodium in the treatment of children with spinal muscular atrophy","volume":"26","author":"Guo","year":"2024","journal-title":"Chin J Contemp Pediatr"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.11675\/j.issn.0253-4304.2023.20.07","article-title":"Clinical effect of nusinersen sodium for the treatment of children with spinal muscular atroph","volume":"45","author":"Zhu","year":"2023","journal-title":"Guangxi Medical Journal"},{"key":"B21","doi-asserted-by":"publisher","first-page":"286","DOI":"10.3969\/j.issn.1673-5501.2023.04.008","article-title":"Nusinersen treatment in 68 children with 5q spinal muscular atrophy:a case series report","volume":"18","author":"Ma","year":"2023","journal-title":"Chin J Evid Based Pediatr"},{"key":"B22","doi-asserted-by":"publisher","first-page":"975","DOI":"10.12083\/SYSJ.231440","article-title":"Correlation of cerebrospinal fluid NF-L and pNF-H with the condition and treatment ofpatients with spinal muscular atrophy","volume":"27","author":"Xu","year":"2024","journal-title":"Chin J Pract Nerv Dis"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1391613","DOI":"10.3389\/fneur.2024.1391613","article-title":"Effects of nusinersen on motor function in children with spinal muscular atrophy: a retrospective study","volume":"15","author":"Chen","year":"2024","journal-title":"Front Neurol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"5378","DOI":"10.1007\/s00415-024-12442-w","article-title":"Nusinersen effectiveness and safety in pediatric patients with 5q-spinal muscular atrophy: a multi-center disease registry in China","volume":"271","author":"Yao","year":"2024","journal-title":"J Neurol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"349","DOI":"10.3233\/JND-230077","article-title":"Treatment of symptomatic spinal muscular atrophy with nusinersen: a prospective longitudinal study on scoliosis progression","volume":"11","author":"Ip","year":"2024","journal-title":"J Neuromuscul Dis"},{"key":"B26","first-page":"204","article-title":"Clinical practice of nusinersen sodium in the treatment of spinal muscular atrophy in children","volume":"57","author":"Shao","year":"2023","journal-title":"J Fujian Med Univ"},{"key":"B27","doi-asserted-by":"publisher","first-page":"944","DOI":"10.7652\/jdyxb202306016","article-title":"Nusinersen treatment in patients with spinal muscular atrophy: a safety analysis of laboratory parameters","volume":"44","author":"Chen","year":"2023","journal-title":"J Xi\u2019an Jiaotong Univ"},{"key":"B28","first-page":"67","article-title":"A report on the full course management of 5 children with spinal muscular atrophy who received intrathecal nusinersen","volume":"14","author":"Shen","year":"2024","journal-title":"Medical Preface"},{"key":"B29","doi-asserted-by":"publisher","first-page":"308","DOI":"10.13286\/j.1001-5213.2025.03.10","article-title":"Evaluation of motor function efficacy and safety of nusinersen on treating spinal muscular atrophy with various types","volume":"45","author":"Li","year":"2025","journal-title":"Chin J Hosp Pharm"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1007\/s12325-024-02852-7","article-title":"A post-marketing surveillance study of nusinersen for spinal muscular atrophy in routine medical practice in China: interim results","volume":"41","author":"Jiang","year":"2024","journal-title":"Adv Ther"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1294405","DOI":"10.3389\/fped","article-title":"Study on the efficacy, safety, and biomarkers of nusinersen in type II and III spinal muscular atrophy in children","volume":"11","author":"Chen","year":"2023","journal-title":"Front Pediatr"},{"key":"B32","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.pediatrneurol","article-title":"1 A prospective cohort study on quantitative muscle magnetic resonance imaging during the treatment of spinal muscular atrophy types 2 and 3 in children","volume":"169","author":"Huang","year":"2025","journal-title":"Pediatr Neurol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s13023-025-03603-9","article-title":"Real-world analysis of the efficacy and safety of nusinersen in pediatric patients with spinal muscular atrophy","volume":"20","author":"Li","year":"2025","journal-title":"Orphanet J Rare Dis"},{"key":"B34","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/s13023-025-03730-3","article-title":"Serum creatinine to cystatin C ratio as monitoring biomarker in Chinese adult spinal muscular atrophy: a prospective cohort study","volume":"20","author":"Chen","year":"2025","journal-title":"Orphanet J Rare Dis"},{"key":"B35","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3969\/j.issn.1006-4931","article-title":"Clinical safety analysis of nusinersen for spinal muscular atrophy","volume":"34","author":"Wang","year":"2025","journal-title":"China Pharm"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.3969\/j.issn.1009-6469","article-title":"Real-world study:efficacy and safety of nusinersen in 61 childrenwith spinal muscular atrophy","volume":"29","author":"Wu","year":"2025","journal-title":"Anhui Med Pharm J"},{"key":"B37","volume-title":"Efficacy Evaluation of Nusinersen in 29 Adolescents and Adults with Spinal Muscular Atrophy:a Real-world cohort Study","author":"Wang","year":"2023"},{"key":"B38","doi-asserted-by":"publisher","first-page":"104316","DOI":"10.1016\/j.braindev","article-title":"Motor function and compound muscle action potential amplitude in children with spinal muscular atrophy treated with nusinersen","volume":"47","author":"Peng","year":"2025","journal-title":"Brain Dev"},{"key":"B39","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1007\/s12519-025-00938-y","article-title":"Sustainable efficacy of nusinersen in children with later-onset spinal muscular atrophy: a 3-year observational study","volume":"21","author":"Feng","year":"2025","journal-title":"World J Pediatr"},{"key":"B40","doi-asserted-by":"publisher","first-page":"727","DOI":"10.12372\/jcp.2025.24e1128","article-title":"Efficacy and safety of nusinersen in spinal muscular atrophy patients with scoliosis","volume":"43","author":"Liu","year":"2025","journal-title":"J Clin Pediatr"},{"key":"B41","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1007\/s12325-025-03475-2","article-title":"Ffectiveness and safety of nusinersen among adults with 5q-spinal muscular atrophy: a multicenter disease registry in China","volume":"43","author":"Dai","year":"2026","journal-title":"Adv Ther"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N Engl J Med"},{"key":"B43","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/nrneurol","article-title":"Spinal muscular atrophy\u2013recent therapeutic advances for an old challenge","volume":"11","author":"Faravelli","year":"2015","journal-title":"Nat Rev Neurol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"420","DOI":"10.3969\/j.issn.1673-5501.2022.06.003","article-title":"Natural history of spinal muscular atrophy: a systematic review and meta-analysis","volume":"17","author":"Hu","year":"2022","journal-title":"Chin JEvid Based Pediatr"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1002\/ana.25900","article-title":"Clinical variability in spinal muscular atrophy type III","volume":"88","author":"Coratti","year":"2020","journal-title":"Ann Neurol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1002\/mus.27384","article-title":"Different trajectories in upper limb and gross motor function in spinal muscular atrophy","volume":"64","author":"Coratti","year":"2021","journal-title":"Muscle Nerve"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1212\/WNL.0b013e318271f7e4","article-title":"Prospective cohort study of spinal muscular atrophy types 2 and 3","volume":"79","author":"Kaufmann","year":"2012","journal-title":"Neurology"},{"key":"B48","doi-asserted-by":"publisher","first-page":"e1988","DOI":"10.1212\/WNL.0000000000010540","article-title":"Muscle strength and motor function in adolescents and adults with spinal muscular atrophy","volume":"95","author":"Wijngaarde","year":"2020","journal-title":"Neurology"},{"key":"B49","doi-asserted-by":"publisher","first-page":"e0199657","DOI":"10.1371\/journal.pone.0199657","article-title":"Ambulatory function in spinal muscular atrophy: age-related patterns of progression","volume":"13","author":"Montes","year":"2018","journal-title":"PLoS One"},{"key":"B50","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.nmd.2014.11.008","article-title":"Upper limb module in non-ambulant patients with spinal muscular atrophy: 12 month changes","volume":"25","author":"Sivo","year":"2015","journal-title":"Neuromuscul Disord"},{"key":"B51","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.nmd.2020.07.005","article-title":"Age and baseline values predict 12 and 24-month functional changes in type 2 SMA","volume":"30","author":"Coratti","year":"2020","journal-title":"Neuromuscul Disord"},{"key":"B52","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus sham control in later-onset spinal muscular atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N Engl J Med"},{"key":"B53","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1002\/acn3.70274","article-title":"Effectiveness and safety of nusinersen and risdiplam in spinal muscular atrophy: a systematic review","volume":"13","author":"Mehrabian","year":"2026","journal-title":"Ann Clin Transl Neurol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1007\/s40120-024-00653-2","article-title":"Effectiveness of nusinersen in adolescents and adults with spinal muscular atrophy: systematic review and meta-analysis","volume":"13","author":"Hagenacker","year":"2024","journal-title":"Neurol Ther"},{"key":"B55","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1186\/s13023-021-02065-z","article-title":"Motor function in type 2 and 3 SMA patients treated with nusinersen: a critical review and meta-analysis","volume":"16","author":"Coratti","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1152318","DOI":"10.3389\/fped.2023.1152318","article-title":"Adverse events in the treatment of spinal muscular atrophy in children and adolescents with nusinersen: a systematic review and meta-analysis","volume":"11","author":"Zhong","year":"2023","journal-title":"Front Pediatr"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/JND-190424","article-title":"Advances in treatment of spinal muscular atrophy - new phenotypes, new challenges, new implications for care","volume":"7","author":"Schorling","year":"2020","journal-title":"J Neuromuscul Dis"},{"key":"B58","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1177\/0333102412453951","article-title":"Post-dural (post-lumbar) puncture headache: risk factors and clinical features","volume":"32","author":"Amorim","year":"2012","journal-title":"Cephalalgia"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.13286\/j.1001-5213.2021.16.12","article-title":"Real-world study of adverse reactions of nusinersen based upon openFDA","volume":"41","author":"Fu","year":"2021","journal-title":"Chin J Hosp Pharm"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2026.1767428\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T06:47:44Z","timestamp":1773384464000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2026.1767428\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":59,"alternative-id":["10.3389\/fped.2026.1767428"],"URL":"https:\/\/doi.org\/10.3389\/fped.2026.1767428","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,13]]},"article-number":"1767428"}}